Earendil Labs secures exclusive global rights to WuXi XDC’s WuXiTecan-2 payload-linker technology in a potential $885M ADC collaboration targeting cancer and autoimmune diseases through AI-driven antibodies.
Written by: Kattarasala Dharan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
WuXi XDC Cayman Inc, a global leader in contract research, development, and manufacturing for antibody-drug conjugates (ADCs) and bioconjugates, has forged a strategic alliance with AI-driven biotech Earendil Labs.
Announced on 27 February 2026, the partnership centers on WuXi XDC’s proprietary WuXiTecan-2 payload-linker technology platform, granting Earendil an exclusive global license for use against multiple specific targets in autoimmune diseases, cancer, and other unmet needs.
Under the deal, Earendil will apply its AI platform to discover and develop antibodies and bispecific antibodies, conjugating them with WuXiTecan-2 to create next-generation ADCs. The agreement holds massive potential value up to $885 million including upfront payments, development/regulatory/sales milestones, and tiered royalties on net sales for commercialized products.
WuXi XDC will handle full chemical, manufacturing, and controls (CMC) support, while Earendil drives product development, regulatory filings, and commercialization.
This synergy pairs Earendil’s AI-powered antibody innovation producing bispecific with unique advantages with WuXi XDC’s end-to-end CRDMO platform, aiming to accelerate safer, more effective ADCs.
As ADCs gain traction in oncology and beyond (e.g., recent approvals like Enhertu and Trodelvy), such tech integrations address key challenges like payload stability, bystander effects, and tumor targeting.
WuXi XDC CEO Jimmy Li, PhD, emphasized the milestone: “This collaboration demonstrates WuXiTecan-2’s value and empowers Earendil’s AI-generated bispecifics for better ADCs. We’ll support their R&D and commercialization via our integrated services, benefiting patients worldwide.”
Earendil Labs CEO Jian Peng, PhD, added: “Partnering with WuXi XDC fuses AI exploration with proven ADC manufacturing, driving biopharma breakthroughs.”
President Zhenping Zhu, MD, PhD, noted: “WuXiTecan-2 will boost our bispecific/multi-specific ADC pipeline’s success rate and speed for transformative therapies.”
This deal underscores the rising role of AI in biologics discovery and CRDMOs in scaling ADC pipelines, potentially fast-tracking candidates to clinic amid a booming market projected to exceed $20B by 2030.
References
WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform, 27 February 2026, https://wuxixdc.com/wuxi-xdc-enters-strategic-collaboration-with-earendil-labs-on-wuxitecan-2-payload-linker-technology-platform/
About Writer
Katherashala Dharan Kumar , PharmD
A dedicated Clinical Researcher with expertise in medical and scientific writing clinical trials, drug safety, and healthcare innovation. Actively contributes to research publications and clinical documentation focused on improving patient outcomes through evidence-based practices and ethical research standards. Believe that every complex data point has a human story waiting to be told. Focusing on providing actionable insights for clinical research.